SAN DIEGO, July 27, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, Ph.D., Bionano’s president and chief executive officer will present at the Canaccord Genuity 43rd Annual Growth Conference on August 10, 2023.
Conference & Webcast Details
| Date: | Thursday, August 10th, 2023 |
| Time: | 11:30 a.m. to 11:55 a.m. ET |
| Presenter: | Erik Holmlin, Ph.D., CEO of Bionano |
| Webcast: | /webcast/canaccord89/register.aspx?conf=canaccord89&page=bngo&url=https://wsw.com/webcast/canaccord89/bngo/2447258 |
A replay / recording of the session will be available following the conference through the Bionano website at https://ir.bionano.com/ for at least 30 days.
About the Canaccord Genuity 43rd Annual Growth Conference
This annual event brings together institutional investors from across the globe with some of the best and most promising growth companies in Canaccord Genuity’s core sectors - Technology, Healthcare & Life Sciences, Sustainability, Industrials, and Consumer & Retail.
About Bionano
Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. The Company also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. The Company additionally offers nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. For more information, visit www.bionano.com, www.bionanolaboratories.com or www.purigenbio.com.
CONTACTS
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations:
David Holmes
Gilmartin Group
+1 (858) 888-7625
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$4.10 |
| Daily Change: | 0.05 1.23 |
| Daily Volume: | 42,677 |
| Market Cap: | US$573.260M |
April 08, 2025 March 31, 2025 March 18, 2025 March 13, 2025 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
